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Objective: Total hip replacement (THR) is one of the most successful and frequently performed opera-
tions worldwide. Health-related quality of life (HRQOL) is a key outcome measure of surgery. We
investigated mid-term HRQOL after THR in patients with osteoarthritis (OA).
Design: A systematic review of clinical studies published after January 2000 was performed using strict
eligibility criteria. Quality appraisal and data tabulation were performed using pre-determined forms.
Data were synthesised by narrative review and random-effects meta-analysis using standardised
response means. Tau2 and I2 values and Funnel plots were analysed.
Results: 20 studies were included. Mid-term post-operative HRQOL is superior compared to pre-
operative status on qualitative and quantitative analysis. Pooled response means of total Harris Hip
Score (HHS) (P < 0.00001) and combined pain (P ¼ 0.00001) and physical function (P < 0.00001) domains
of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and HHS improved
markedly up to 7 years. Medical Outcomes Survey Short Form 36 shows physical functioning (PF)
(P < 0.00001), bodily pain (BP) (P < 0.00001), role physical (P ¼ 0.001), role emotional (P ¼ 0.04), and
social functioning (SF) (P ¼ 0.03) were improved up to 7 years. General health (GH) (P ¼ 0.29), mental
health (MH) (P ¼ 0.43), and vitality (P ¼ 0.17) was similar. HRQOL is at least as good as reference pop-
ulations in the ﬁrst few years and subsequently plateaus or declines. Patient satisfaction and functional
status was favourable. There was signiﬁcant heterogeneity amongst all studies, but publication bias was
low in pooled analysis.
Conclusion: THR confers signiﬁcant mid-term HRQOL beneﬁts across a broad range of health domains.
Further studies based on consistent guidelines provided in this review are required.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Rationale
Total hip replacement (THR) is one of the most successful sur-
gical procedures and has been identiﬁed as the “operation of the
century”1. Greater than onemillion operations are performed every
year worldwide and this is anticipated to double within the next
decade2. In the USA alone, the number of operations is projected to
rise to 572,000 per year by 20303. An estimated 93% of operations
are performed for severe osteoarthritis (OA) with intractable pain: A. Saxena, Department of
llongong, Australia. Tel: 61-
a).
s Research Society International. Pand functional limitations2. For these patients who are refractory to
conservative measures, THR is currently the recommended and
most effective treatment4.
OA is a serious public health issue with symptomatic disease
prevalent in 9% of men and 11% of women5,6. It is a major cause of
pain and disability7. Age is one of the largest risk factors for
developing OA8. According to the United Nations, the world’s
population is ageing rapidly with the number of people older than
60 years of age projected to double from 11% to 22% (2 billion) by
20509. This will fuel an increasing incidence of OA and demand for
THR10e12.
THR achieves excellent technical outcomes with 10-year sur-
vival exceeding 95%, 25-year implant survival greater than 80%, and
signiﬁcant beneﬁts for pain, mobility, and physical function3,13,14.
However, these traditional indicators of surgical success may not
mirror the patient’s post-operative experience or healthcare ef-
forts15e18. Patients’ expectations after THR have also changed withublished by Elsevier Ltd. All rights reserved.
L. Shan et al. / Osteoarthritis and Cartilage 22 (2014) 389e406390many patients anticipating an active lifestyle in the years after
surgery19. Hence interest in patient-derived assessments of
healthcare and health-related quality of life (HRQOL) has increased
signiﬁcantly.
Post-operative HRQOL is now the key goal of surgery and
measure of operative outcome20. HRQOL is so important in ortho-
paedics that it even constitutes a requirement for publication in
some journals18. Modern series demonstrate good short-term
HRQOL after THR for up to 2 years18,21e23. However, mid-term
HRQOL has been an important issue in THR that remains unan-
swered24e26.
Despite the ageing population, the mean age of THR has not
changed from 70 years in developed countries27,28. Coupled with
excellent long-term patient and prosthesis survival, increasing life
expectancy will lead to more patients living for longer with their
implants. In addition, a greater number of younger patients are
undergoing surgery with 20% of operations being performed in
those under 60 years of age14,29,30. These factors emphasise the
need to analyse HRQOL beyond the early post-operative period. A
thorough evaluation of surgical outcomes is also necessary for
effective resource utilisation31.Objectives
We conducted a systematic review and meta-analysis of articles
published after January 2000 on mid-term HRQOL after THR to (1)
investigate post-operative HRQOL compared to respective patients’
pre-operative status and reference populations, (2) outline sub-
jective post-operative function and satisfaction, (3) clarify
strengths and weaknesses of current evidence, and (4) outline
guidelines for future research.Methods
The structure of this review followed previously recommended
guidelines32 and was written in accordance with the PRISMA
checklist for systematic reviews and meta-analysis33.Deﬁnition and measurement of HRQOL
HRQOL encapsulates an individual’s physical, emotional and
psychological health as well as social and functional status34. The
assessment of these dimensions of health is necessary to evaluate
broad health-related implications of OA and its treatment21. Since
HRQOL is not a tangible entity, a standardised method of mea-
surement is required which is reliable, valid, responsive, sensitive,
and covers all health domains34. This can be achieved by assessing
disease-speciﬁc and generic HRQOL.
Disease-speciﬁc HRQOL measures aim to accurately reﬂect a
patient’s experience of a speciﬁc illness or treatment. Western
Ontario and McMaster University Osteoarthritis Index (WOMAC)35,
Harris Hip Score (HHS)36e38, McMaster University Osteoarthritis
Index (MACTAR)39, Osteoarthritis Knee and Hip Quality of Life
questionnaire (OAKHQOL)40, Merle d’Aubigne-Postel (MAP)41, and
Functional Comorbidity Index (FCI)42 were used in this study.
Generic HRQOL instruments are required to facilitate holistic
assessment of health dimensions43. Medical Outcomes 36-item
Short-Form Health Survey (SF-36)44,45, Medical Outcomes 12-
item Short-Form Health Survey (SF-12)46, Nottingham Health
Proﬁle (NHP)47, Sickness Impact Proﬁle (SIP)48, and World Health
Organisation (WHO) Quality of Life Short Version Instrument
(WHOQOL-BREF)49 were used in this study. Detailed descriptions of
each instrument can be found in Table III.Selection criteria
Studies considered for review had the following pre-determined
inclusion criteria: (1) all patients over 18 years of age, (2) OA as the
primary indication for surgery, (3) THR as a primary procedure, (4)
mid-term outcomes with a mean or ﬁnal post-operative follow-up
of at least 3 years, (5) disease-speciﬁc and/or generic HRQOL data
recorded. These studies were restricted according to the following
report characteristics: (1) published after January 2000, (2) English
language, and (3) original research only. The search period was
restricted to be more representative of modern post-operative
outcomes.
Information sources and search strategy
On December 2012 a literature search was conducted using
MeSH keyword search on PubMed (MEDLINE) for all studies pub-
lished after January 2000 (Fig. 1). Strict inclusion criteria for study
characteristics were applied as described above. An additional
manual search of OVID (MEDLINE) and EBSCOhost (EMBASE) as
well as reference lists of each included study was conducted to
identify studies not covered by the initial MeSH Keyword search. All
identiﬁed articles were retrieved from the aforementioned
databases.
Study selection
Following the search, two reviewers independently performed
the ﬁrst stage of screening titles and abstracts. Studies were
excluded if they did not meet eligibility criteria. If the information
required to determine eligibility was not in the abstract, a second
stage screen was run after data extraction. Consensus for studies to
be included was achieved by discussion between the two reviewers
based on the pre-determined selection criteria mentioned above.
Reviewers were not blinded to any study characteristics including
journal, authors and study institution.
Data items and extraction
All data items were pre-determined and speciﬁed as shown in
Tables I & II. Data extraction was then performed in two parts by
two reviewers using standardised pilot forms. Study quality was
ﬁrst assessed using sample size, study design, use of both disease-
speciﬁc and generic HRQOL measures, follow-up consistency and
variability of results (Table I). Overall level of evidence applicable to
orthopaedic surgery was also assessed50. These were derived from
previously described guidelines32,33. Secondly, HRQOL results of
the studies reviewed were tabulated (Table II).
Synthesis of results
The generic inverse variance method using a random-effects
model was used to estimate the standardised response mean for
continuous data across studies. The pooled response means (esti-
mated overall mean difference [95% conﬁdence interval (CI)]) are
expressed on Forest plots. Low quality studies were analysed, but
excluded from the pooled response means analysis. Disease-
speciﬁc HRQOL instruments were pooled together and likewise
generic HRQOL instruments were pooled together. Some studies
split HRQOL data by characteristics such as gender and cement or
cementless procedures. These separate results were pooled
together to avoid any bias and allow inclusion in meta-analysis. In
order to perform sub-group analyses to elicit outcomes for speciﬁc
health domains, similar health domains within each instrument
were pooled together. Where necessary, HRQOL results were
Table I
Quality appraisal
Author
Year (study period)
Patients Study
design
Methodological quality Precision Overall
Generic HRQOL
instrument
Disease speciﬁc
measures
Patient demographics Follow-up and
assessment methods
Follow-up
consistency
Range/CI/SE/SD
of results
Level of
evidence
Soderman53
2000 (1986e1995)
1056 R YES;
NHP
SF-36
NO Age: 75.5 yrs, Male: 46%, BMI: NR
OA: 89%, Revision: NR, HTN:
NR, Diabetes: NR, Smoking: NR,
CVD: NR, Pulmonary disease: NR,
Anx/Dep: NR
Location: Sweden
Baseline: NR
Follow-up: mail
100% PR
93% RR
Follow-up: NR
QOL: NR
III
Laupacis63
2002 (1987e1992)
250 P YES;
SIP
YES;
HHS
MACTAR
WOMAC
Age: 64 yrs, Male: 52%, BMI: NR
OA: 100%, Revision: 8%, HTN: NR,
Diabetes: NR, Smoking: NR, CVD:
NR, Pulmonary disease: NR, Anx/Dep: NR
Location: Canada
Baseline: Re
Follow-up: NR
100% PR
86% RR
Follow-up: moderate
QOL: wide
I
Kawasaki65
2003 (1999e2000)
287 R YES;
NHP
NO Age: 54 yrs, Male: 0%, BMI: NR
OA: 100%, Revision: NR, HTN: NR,
Diabetes: NR, Smoking: NR, CVD: NR,
Pulmonary disease: NR, Anx/Dep: NR
Location: Japan
Baseline: NR
Follow-up: NR
51% PR
24% RR
Follow-up: wide
QOL: NR
III
Nilsdotter54
2003 (1995e1998)
219 P YES;
SF-36
YES;
WOMAC
Age: 71 yrs, Male: 45%, BMI: NR
OA: 100%, Revision: NR, HTN: 27.8%,
Diabetes: 7.1%, Smoking: NR, CVD: NR,
Pulmonary disease: 0.5%, Anx/Dep: NR
Location: Sweden
Baseline: Re
Follow-up: mail
96% PR
93% RR
Follow-up: moderate
QOL: moderate
II
Butler62
2005 (1990e1992)
107 P YES;
SF-36
YES;
HHS
Age: 63.4 yrs, Male: 42%, BMI: 20.0
(M) 26.4 (F)
OA: 76%, Revision: 1%, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: USA
Baseline: Re
Follow-up:
clinical examination
95% PR
85% RR
Follow-up: narrow
QOL: NR
III
Gotze55
2006 (1986e1990)
201 P YES;
SF-36
Yes;
HHS
Age: 59 yrs, Male: 33%, BMI: 29.7
OA: 58%, Revision:10%, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: Germany
Baseline: NR
Follow-up:
telephone
73% PR
79% RR
Follow-up: NR
QOL: moderate
III
Alfonso61
2007 (1998e2004)
18 R NO YES;
HHS
Age: 91.5 yrs, Male:24 %, BMI: NR
OA: 50%, Revision: 6%, HTN: 64%, Diabetes:
8%, Smoking: NR, CVD: 4%, Pulmonary disease:
24%, Anx/Dep: 4%
Location: USA
Baseline: Re
Follow-up: NR
64% PR
86% RR
Follow-up: moderate
QOL: NR
IV
Cushnaghan7
2007 (1993e1995)
643 P YES;
SF-36
NO Age: NR yrs, Male: 35%, BMI: 30%  24.5,
70%  24.6
OA: 100%, Revision: 4%, HTN: 29.3%, Diabetes:
3.2%, Smoking: 53%, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: UK
Baseline: Re
Follow-up: mail
52% PR
85% RR
Follow-up: narrow
QOL: moderate
III
Lubbeke66
2007 (1996e2000)
435 P YES;
SF-12
YES;
WOMAC
HHS
Age: 68.4 yrs, Male: 46%, BMI: 79%  30 21%  30
OA: 77.5%, Revision: NA, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: Switzerland
Baseline: NR
Follow-up:
telephone, mail
and clinical
examination
88.3% PR
79%RR
Follow-up: narrow
QOL: narrow
II
Ng64
2007 (1998e2000)
627 P YES;
SF-36
YES;
HHS
Age: 68 yrs, Male: 38%, BMI: NR
OA: 92.5%, Revision: 2%, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: Scotland
Baseline: Re
Follow-up:
research audit
nurse
89% PR
60e70% RR
Follow-up: NR
QOL: moderate
II
(continued on next page)
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Table I (continued )
Author
Year (study period)
Patients Study
design
Methodological quality Precision Overall
Generic HRQOL
instrument
Disease speciﬁc
measures
Patient demographics Follow-up and
assessment methods
Follow-up
consistency
Range/CI/SE/SD
of results
Level of
evidence
Busija45
2008 (NR)
274 R YES;
SF-36
NO Age: 70.5 yrs, Male: 47%, BMI: NR
OA: 100%, Revision: NR, HTN: NR,
Diabetes: NR, Smoking: NR, CVD:
NR, Pulmonary disease: NR, Anx/Dep: NR
Location: Sweden
Baseline: Re
Follow-up: NR
93% PR
65% RR
Follow-up: NR
QOL: moderate
III
Shi59
2008 (1997e2000)
383 P YES;
SF-36
YES;
HHS
Age: 58  14.67 yrs, Male: 58%, BMI: NR
OA: 52%%, Revision: NR, HTN: NR,
Diabetes: NR, Smoking: NR, CVD: NR,
Pulmonary disease: NR, Anx/Dep: NR
Location: Taiwan
Baseline: Re
Follow-up:
clinical
examination
100% PR
58% RR
Follow-up: NR
QOL: wide
II
Bhandari67
2009 (1993e2000)
1152 R NO YES;
WOMAC
Age: 65.3 yrs, Male:47.5 %, BMI: 28
OA: 93%, Revision: 11%, HTN: NR,
Diabetes: NR Smoking: NR, CVD: NR,
Pulmonary disease: NR, Anx/Dep: NR
Location: Canada
Baseline: Re
Follow-up:
clinical
examination
NR% PR
27% RR
Follow-up: NR
QOL: narrow
III
Shi60
2009 (1998e2002)
335 P YES;
SF-36
YES;
HHS
Age: 59.8 yrs, Male: 56.7%, BMI: NR
OA: 52%, Revision: NR, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: Taiwan
Baseline: Re
Follow-up: NR
96% PR
41% RR
Follow-up: NR
QOL: moderate
III
Shi20
2009 (1997e2000)
335 P YES;
SF-36
YES;
HHS
Age: 59.8 yrs, Male: 57.6%, BMI: NR
OA: 52.2%, Revision: NR, HTN: 19.1%,
Diabetes: 11.6%, Smoking: NR, CVD: NR,
Pulmonary disease: 1.5%, Anx/Dep: NR
Location: Taiwan
Baseline: Re
Follow-up:
clinical
examination
100% PR
55% RR
Follow-up: NR
QOL: moderate
III
Nilsdotter26
2010 (1995e1998)
219 P YES;
SF-36
YES;
WOMAC
Age: 71 yrs, Male: 45%, BMI: NR
OA: 100%, Revision: 0%. HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: Sweden
Baseline: Re
Follow-up: mail
79% PR
88% RR
Follow-up: NR
QOL: moderate
II
Rat25
2010 (1994e2003)
3 yrs: 232
10 yrs: 221
P YES;
SF-36
NHP
WHOQOL
YES;
HHS
OAKHQOL
WOMAC
Age: 72.4 yrs, Male: NR%, BMI: NR
OA: 100%, Revision: 0%, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: France
Baseline: Re
Follow-up: mail
3 yrs:
99% PR
84% RR
10 yrs:
58% PR
69% RR
Follow-up: NR
QOL: moderate
II
Hossain56
2011 (1999e2002)
448 P YES;
SF-36
NO Age: 64.5 yrs, Male: 40%, BMI: NR
OA: 80.6%, Revision: 0%, HTN: NR, Diabetes:
NR, Smoking: NR, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: UK
Baseline: Re
Follow-up:
clinical
examination
NR PR
55% RR
Follow-up: NR
QOL: wide
II
Lavernia58
2011 (1993e2007)
568 R YES;
SF-36
YES;
WOMAC
HHS
MAP
Age: 61  15 yrs, Male: 41%, BMI: 28.8
OA: 100%%, Revision: 0%, HTN: NR,
Diabetes: NR, Smoking: NR, CVD: NR,
Pulmonary disease: NR, Anx/Dep: NR
Location: USA
Baseline: Re
Follow-up: NR
95% PR
98% RR
Follow-up: narrow
QOL: wide
III
Mariconda57
2011 (1985e1996)
412 R YES;
SF-36
YES;
WOMAC
HHS
FCI
Age: 55.3 yrs, Male: 35.2%, BMI: 27.0
OA: 76%, Revision: 8%, HTN: NR, Diabetes:
NR, Smoking: 28.8%, CVD: NR, Pulmonary
disease: NR, Anx/Dep: NR
Location: Italy
Baseline: NR
Follow-up:
telephone or
clinical examination
Repeat attempts NR
72% PR
84% RR
Follow-up: moderate
QOL: Moderate
III
Abbreviations: Anx/Dep e anxiety/depression; BMI e body mass index; CVD e cerebrovascular disease; M e men; MCS e mental component summary score; NR e not recorded; P e prospective; PCS e physical component
summary score; PR e participation rate; R e retrospective; Re e recorded; RE e role emotional; RP e role physical; SE e standard error; SF-12 emedical outcomes survey short form 12 questions; SF-36 emedical outcomes
survey short form 36 questions; THR e total hip replacement; VT e vitality; W e women.
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Table II
Results of included studies
Author (year) Objective Comparison group Follow-up interval Conclusions
HRQOL measure Results
Soderman53 (2000) To validate the end-point for failure in the Swedish national THR register, and
to study GH after THR.
Post-op 2 yrs vs 10 yrs 2e10 yrs 10-yrs generic HRQOL is
comparable to early follow-up.
Disease speciﬁc measures NR
Generic instruments All scores compared 10 yrs vs 2 yrs.
NHP: Total score (24 vs 15), pain (25 vs 17), energy (35 vs 20), sleep (26 vs 16), physical motion (35 vs 22), emotional
reaction (15 vs 7.7), and social isolation (9.2 vs 4.9) worsened with time.
SF-36: Total score (60 vs 70), PF (42 vs 58), RP (41 vs 54), BP (58 vs 73), GH (62 vs 66), VT (54 vs 66), SF (77 vs 86), RE
(58 vs 67), and MH (75 vs 81) were slightly worse.
Please refer to original article for detailed quantitative results.
Function NR
Laupacis63 (2002) To compare the ﬁxation of a Mallory-Head total hip prosthesis with and
without cement.
Cemented vs cementless
Post-op vs pre-op
Mean
6.3  2.3 yrs
Broad improvements for both
disease-speciﬁc and generic
HRQOL.
THR has a dramatic and
sustained positive effect on
HRQOL.
Disease speciﬁc measures All outcome measures improved substantially by 3 months after surgery which is followed by continued small
improvement to 1 yr. Despite a slight worsening, superior post-op HRQOL is maintained over 7 yrs.
All scores provided as change scores [7 yrs; 3 months].
WOMAC: Improvements were sustained for cement: pain (4.4  2.0; 4.2  1.9), stiffness (4.0  3.1; 3.7  2.3),
physical function (4.7  2.4; 4.2  1.9); and cementless: pain (3.6  2.2; 4.3  2.0), stiffness (4.3  3.1;
4.3  1.9), and physical function (4.3  2.4; 4.3  1.8).
HHS: Scores improved markedly for both cement (44  15; 41  12) and cementless (46  14; 41  11)
MACTAR improved as well for cement (6.2  2.8; 5.3  2.5) and cementless: (6.0  2.6; 5.2  2.2)
Generic instruments SIP: There were substantial gains in global physical score for cement (18 12;15 11) and cementless (17  9;
14  12).
Please refer to original article for detailed quantitative results.
Function NR
Kawasaki65 (2003) To examine HRQOL after a rotational acetabular osteotomy, primary THR, or
conservative treatment.
General reference population
Conservative treatment
Mean
3.9 yrs
(0.5e20.0)
Generic HRQOL did not reach
general population norms.
Physical mobility was the main
beneﬁciary of surgery.Disease speciﬁc measures NR
Generic instruments NHP: [THR vs reference population, more than 5 yrs post-op] Energy (37 vs 27, P > 0.05), physical mobility (45 vs 10,
P< 0.01), pain (31 vs 12, P> 0.05), sleep (20 vs 18, P> 0.05), emotional reaction (14 vs 8, P> 0.05), and social isolation
(2 vs 3, P> 0.05) did not reach population level. No signiﬁcant differences were found between THR and conservative
treatment.
Function NR
Nilsdotter54 (2003) To investigate the long-term patient-relevant outcomes after unilateral THR
for OA.
Age, sex and municipality-
matched population
Post-op vs pre-op
Mean
3.6 yrs
(2.1e5.4)
Disease-speciﬁc and generic
HRQOL improved compared to
pre-op.
SF-36 scores improved in
almost all dimensions
compared to baseline.
Similar scores were attained
compared to the reference
population, but disease-speciﬁc
HRQOL was worse.
Poorer physical function than a
matched reference group
without hip complaints may be
explained by the presence of
musculoskeletal comorbidities.
Disease speciﬁc measures WOMAC: [post-op vs pre-op] The authors re-modelled the scale so that increasing score reﬂected better outcomes.
Pain (82  20.3 vs 45  17.2), stiffness (78  22.2 vs 39  16.3), function (74  21.7 vs 38  14.8) improved markedly
(P < 0.0001). [THR vs general population] Pain (82 vs 87, P ¼ 0.006) and function (74 vs 84, P < 0.0001) was not as
good.
Generic instruments SF-36: [post-op vs pre-op] PF (60  25.1 vs 30  19.6), RP (48  44.0 vs 9  21.4), BP (66  26.2 vs 30  16.8), VT
(64  24.3 vs 49  20.9), SF (84  22.6 vs 64  26.2), RE (65  42.4 vs 37  42.5), and MH (78  20.1 vs 70  21.0)
improved. GH (66  22.0 vs 68  19.9) was similar.
There were no differences in the SF-36 subscales between patients and the reference group except PF (60 vs 71,
P < 0.0001).
Function Satisfaction: Only 4% of all patients reported that they were dissatisﬁed with the results of the THR.
Butler62 (2005) To assess the durability and clinical outcomes of the anatomically designed,
porous-coated femoral implant in a wide range of patients typically
encountered in a community orthopaedic practice.
Post-op vs pre-op
General reference population
Mean 11 yrs
(10e12)
Substantial improvements in
disease-speciﬁc and generic
HRQOL.
Generic HRQOL can compare toDisease speciﬁc measures:
(continued on next page)
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Table II (continued )
Author (year) Objective Comparison group Follow-up interval Conclusions
HRQOL measure Results
general population norms.
Excellent clinical and
radiographic results are
obtained with the anatomically
designed stem and are based on
a longer follow-up interval than
previous reports.
HHS: [post-op vs pre-op] Pain (42.78  8.22 vs 14.21  6.89) and total score (95.98  9.08 vs 42.21  3.13) had
dramatic improvements.
Generic instruments: SF-36: [post-op vs pre-op] PF
(M-45.8 F-2.8. vs M-73.1 F-
55.9), PR (M-30.9 F-10.2 vs M-
67.8 F64.9), and BP (M-33.8
F-30.9 vs M-66.9 F-64.8)
beneﬁted the most. There was a
small decrease in scores in GH
(M-76.1 F-74.9 vs M-70.2
F-73.9) and RE (M-86.0 F-56.1
vs M-79.8 vs F-81.9). [THR vs
reference population] PF, PR,
and MH scores were higher or
equal to those of the general
population. Quantitative results
NR.
Function All patients allowed to progress to full weight bearing on the ﬁrst post-op day as balance and conﬁdence permitted.
All patients without comorbid conditions necessitating external support progressed to an unassisted limp-free gait
usually within 3e6 weeks.
Gotze55 (2006) To assess the efﬁcacy of the Metal-Cancellous Cementless Lubeck
endoprosthesis implant with a fully coated stem in a long-term study.
Age-matched healthy
population
Mean
12.8 yrs
(10.1e14.9)
Generic HRQOL is similar to
age-matched population
norms.
Metal-cancellous acetabular
component was conﬁrmed to
be a reliable implant up to 15
yrs post-op.
Disease speciﬁc measures HHS: total score (88.3), pain (33.8), activity (11.8), mobility (27.7) and function (4.8).
Generic instruments SF-36: [THR vs reference population>70 yrs] PF (58 vs 60), RP (55 vs 62), BP (62 vs 62), GH (46 vs 46), VT (54 vs 55), SF
(84 vs 83), and MH (70 vs 70) were similar.
Function NR
Alfonso61 (2007) To review experience with THR in patients 90 yrs of age and older for the
purpose of determining what measures can be taken to make surgery in this
age group safer.
Post-op vs pre-op Mean
4.1 yrs
(1.8e8.1)
Disease-speciﬁc HRQOL
beneﬁts post-op.
Due to the small number of
patients undergoing THR, no
signiﬁcant conclusions can be
reached concerning this group
taken separately.
THR in nonagenarians may
allow patients to be more pain
free, more active, and healthier.
Disease speciﬁc measures HHS [post-op vs pre-op]: total (28 vs 62)
Generic Instruments NR
Function NR
Cushnaghan7 (2007) To assess the long-term outcome and predictors of prognosis following THR for
OA.
Age, sex and GP-matched
population
Post-op vs pre-op
8.5 yrs
(7.1e9.9)
Generic HRQOL is improves, but
not to the level of age-matched
populations.
Beneﬁts for PF are sustained in
the longer term, and greatest in
the patients who have the most
severe radiographic changes of
OA before surgery.
Disease speciﬁc measures NR
Generic instruments SF-36: [post-op vs pre-op] PF (30 vs 20), MH (76 vs 64), and VT (50 vs 60) were superior. [THR vs reference
population]: PF (30 vs 65, P < 0.0001) and VT (50 vs 60, P < 0.0001), were worse, but MH (76 vs 80, P ¼ 0.25) was
similar.
Function NR
Lubbeke66 (2007) To compare general and disease-speciﬁc QOL and patient satisfaction in
patients with primary and revision THR.
Primary vs revision patients 5-yrs Functional outcome and
satisfaction is lower after
revision THR than after primary
THR, but the difference is partly
explained by older age and
greater morbidity of patients
undergoing revision THR.
Disease speciﬁc measures HHS: [primary THR vs revision THR] (88.1  13.1 vs 76.7  18.1)
WOMAC [primary THR vs revision THR]: Pain (73.3  22.5 vs 66.4  24.0) and function (70.0  22.3 vs 61.6  22.9)
Generic instruments SF-12: [primary THR vs revision THR] PCS (41.1  9.7 vs 36.5  8.6) and MCS (46.6  10.5 vs 46.5  11.2)
Function Satisfaction: [primary THR vs revision THR]: (8.9 vs 7.7). Satisfaction scores were high (scores  8) in 84% of primary
THR patients, compared to 67% of revision THR patients.
Ng64 (2007) To evaluate the QOL and functional outcome after unilateral primary THR. Post-op vs pre-op 6, 18-months, 3, 5-yrs Disease-speciﬁc HRQOL had
signiﬁcant improvement up to
18 months, after which there is
a decline.
Disease speciﬁc measures HHS: The greatest change occurred between the pre-op assessment and the review at 6 months (P < 0.001). Between
6 and 18 months there was a further small, but signiﬁcant improvement (P < 0.001). Following that the scores
plateaued.
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HRQOL remains above the
pre-op level.
Results conﬁrm the
sustainability of the beneﬁts of
THR, even though there is a
decline in certain SF-36
dimensions after 18 months.
Generic instruments SF-36: Mean scores of all dimensions except GH and MH improved signiﬁcantly following operation and remained so
throughout the entire follow-up period (P < 0.001). Between 18 months and 3 yrs there was a signiﬁcant decrease in
mean VT (P ¼ 0.014), BP (P ¼ 0.014) and changes in health scores (P < 0.001). Between the 3 and 5 yrs reviews there
was a signiﬁcant drop in the mean scores of PF (P < 0.001), SF (P ¼ 0.042), BP (P ¼ 0.042) and changes in health
(P ¼ 0.021).
Quantitative results NR.
Function NR
Busija45 (2008) To examine the magnitude and meaningfulness of change and sensitivity of
SF-36 subscales following THR.
Age and sex-matched
population
Post-op vs pre-op
6 months, 5 yrs Generic HRQOL has marked
improvements post-op and is
comparable to an age-matched
population.
The SF-36 can be used to show
changes for groups in physical,
mental and social dimensions
and in comparison with
population norms.
Disease speciﬁc measures NR
Generic instruments SF-36: [post-op vs pre-op] PF (57.6  27.3 vs 30.7  20.1), RP (49.6  43.2 vs 8.5  20.2), BP (67.1  26.0 vs
30.9  17.2), VT (64.3  22.4 vs 50.9  20.1), SF (84.3  22.3 vs 65.  26.2), RE (65.5  42.0 vs 39.3  43.6) and MH
(80.6  17.9 vs 69.8  17.7) improved markedly. GH (63.6  22.9 vs 68.8  19.1) was similar. [post-op THR vs
reference population] PF (74.5  24.1 vs 57.6  27.3) was better. GH (63.6  22.9 vs 61.8  22.7), VT (64.3  22.4 vs
63.8 22.6), and SF (84.3 22.3 vs 82.7 2.40) were comparable. MH (80.6 17.9 vs 82.0 15.6), RP (49.6 43.2 vs
60.1  42.4), BP (67.1  26.0 vs 70.2  28.0), and RE (65.5  42.0 vs 77.5  40.9) were slightly worse.
Function NR
Shi59 (2008) To examine the longitudinal changes in HRQOL over time after THR starting
from before surgery. The performance of each of the dimensions of HRQOL
over time with the average QOL for the general population in Taiwan was
compared.
General reference population
Post-op vs pre-op
3-, 6-months, 1-, 2-, 5-, 6-, 7-yrs Dramatic improvements in
disease-speciﬁc and generic
HRQOL.
MCS of THR patients improves
rapidly after surgery and
becomes higher than the
average score for the general
population.
PCS of THR patients tends not to
surpass the norm.
However, since the THR
patients are older than the
general population, achieving
the average PCS norm indicates
the positive impact THR has on
QOL.
Disease speciﬁc measures HHS: [5 yrs post-op vs pre-op]: Pain (41.91  3.25 vs 18.07  8.40), function (41.15  6.91 vs 22.10  8.98), and total
score (92.87  8.67 vs 46.79  15.3) had dramatic improvements.
Generic instruments SF-36: [5 yrs post-op vs pre-op] All domains improved markedly as shown: PF (85.43  20.1 vs 41.51  21.1), RP
(87.60 31.9 vs 14.10 29.8), BP (50.14 4.41 vs 44.55 9.53), GH (75.06 19.8 vs 52.32 19.8), VT (78.47 19.84
vs 59.41  18.6), SF (91.07  16.1 vs 50.45  23.7), RE (90.08  27.3 vs 38.38  44.0), MH (80.60  17.3 vs
66.13  15.8), PCS (44.01  .060 vs 24.13 .0.51), and MCS (60.13  0.85 vs 47.43  0.60). [5 yrs post-op vs reference
population]: RP (92.9 vs 83.7), GH (81.3 vs 69.3), VT (84.3 vs 68.3), SF (92.8 vs 86.8), RE (94.1 vs 79.4), and MH (84.9 vs
73) was better; PF (91.2 vs 92.2) was similar; and BP (49.7 vs 84.8) was worse.
Please refer to original article for detailed quantitative results.
Function NR
Bhandari67 (2009) To improve knowledge about surgical technique, particularly outcomes
following elective THR using the anterior surgical approach.
Different surgery populations 3, 6, 12, 24 and 36 months Disease-speciﬁc HRQOL
improves, but may decline after
6 months.
The anterior approach to THR
with an orthopaedic table is a
safe approach, with results
generalizable to surgeons with
variable surgical experience.
Disease speciﬁc measures WOMAC: Pain (Pre-op 75.1  19.8, 3 months 96.6  3.1, 6 months 90.4  12.2, 1 yr 91.3  13.0, 2 yrs 93.1  8.3, 3 yrs
93.3  1.9) scores improved over time while function scores (Pre-op e 45.3  12.2, 3 months e 88.1  9.9, 6 months
e 83.4  15.3, 1 yr e 83.4  14.7, 2 yrs e 82.0  13.4, 3 yrs e 77.3  6.5) decline, but remain above pre-op levels.
Generic instruments NR
Function All but 24 patients used an assistive device at discharge from hospital. Assistive devices were discontinued at a mean
21 days, however 80% of patients no longer used an assistive device by 4 days after hospital discharge.
Shi60 (2009) To examine the longitudinal changes in each SF-36 subscale and explore their
relationships to effective predictors in primary THR patients.
General reference population
Pre-op vs post-op
3-, 6-months, 1-, 2-, 5-yrs Generic HRQOL improves
compared to pre-op, but does
not quite reach population
norms.
Performance in all SF-36
domains except BP as well as
PCS and MCS subscales
improved signiﬁcantly during
the ﬁrst 3 months after
discharge and persisted for the
following 5 yrs.
Disease speciﬁc measures HHS: pain [post-op] (18.15  8.55), function [pre-op] (22.31  9.15).
Generic instruments SF-36: [5 yrs post-op vs pre-op] PF (87.85 1.78 vs 39.81 3.94, P< 0.01), RP (90.28 2.47 vs 12.17 5.91, P< 0.01),
VT (82.94  1.71 vs 56.21  3.26, P < 0.01), SF (94.99  1.66 vs 60.88  3.75, P < 0.01), and RE (95.10  3.21 vs
43.64  6.11, P < 0.05) had dramatic improvements whilst BP (49.84  0.63 vs 42.28  1.29, P > 0.05), GH
(79.85 1.57 vs 52.05 3.17, P< 0.01), MH (83.13 1.62 vs 61.95 2.67, P< 0.01), PCS (43.29 0.63 vs 25.76 1.51,
P < 0.01), and MCS (59.93  0.87 vs 47.71  1.53, P < 0.01) also improved. [THR vs general population] PCS did not
reach population norms. Quantitative results NR.
Please refer to original article for detailed quantitative results.
Function NR
Shi20 (2009) To compare the responsiveness over time of the HHS and the SF-36 in patients
who underwent THR and assess variation in the irresponsiveness by the
number of comorbid conditions.
Post-op vs pre-op 6 months, 1, 2, 5 yrs Disease-speciﬁc and generic
HRQOL improved dramatically.
Disease-speciﬁc measures are
more accurate for assessing
immediate effects, whereas
Disease speciﬁc measures HHS: [5 yrs post-op vs pre-op] Pain (41.2 vs 17.5), function (38.3 vs 19.0), and total score (88.5 vs 42.3) improved
dramatically.
(continued on next page)
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Table II (continued )
Author (year) Objective Comparison group Follow-up interval Conclusions
HRQOL measure Results
generic measures are more
appropriate for revealing the
long-term effects of an
intervention on overall
function.
Generic instruments SF-36 [5 yrs post-op vs pre-op]: PF (83.8 vs 31.5, P < 0.01) and SF (91.8 vs 47.5, P < 0.01) more than doubled. BP (53.7
vs 48.1, P> 0.05), VT (71.4 vs 45.1, P< 0.01), MH (74.3 vs 54.3, P < 0.01), GH (77.6 vs 45.7, P< 0.01), PCS (44.1 vs 22.6,
P < 0.01), and MCS (54.9 vs 42.1, P < 0.01) all improved.
Please refer to original article for detailed quantitative results.
Function NR
Nilsdotter26 (2010) To investigate the patient-relevant outcome 7 yrs after THR for OAwith a focus
on pain and physical function.
Age, sex and municipality-
matched population
Post-op vs pre-op
4, 5, 7 yrs Disease-speciﬁc and generic
HRQOL improves compared to
pre-op and can be comparable
to age-matched populations.
Patients experience a similar
health-related QOL as a
reference group of a similar age
and sex 7 yrs after THR except
for PF where the patients score
worse.
THR for OA is a successful
procedure, with a marked
change in most of the measures
from before to after surgery.
Disease speciﬁc measures WOMAC: [7 yrs post-op vs pre-op] Pain (86  16.5 vs 44  16.5), stiffness (78  22.1 vs 38  15.9), and function
(76 21.1 vs 38 14.8), P< 0.001were much better for all domains. [THR vs reference population] Pain (86 16.5 vs
91  18.2, P¼ 0.05) and stiffness (78  22.1 vs 89  22.0, P< 0.001) were worse, but function (76  21.1 vs 73  23.8,
P ¼ 0.56) was similar.
Generic instruments SF-36: [7 yrs post-op vs pre-op] PF (54  27.2 vs 31  19.4, P < 0.001), RP (45  44.6 vs 9  21.1, P ¼ 0.001), BP
(63  28.1 vs 31  15.8, P < 0.0001), MH (79  19.1 vs 70  21.2, P ¼ 0.03), and VT (59  46.4 vs 49  20.2, P ¼ 0.003)
improved. SF (62  23.8 vs 63  26.4, P < 0.0001) and GH (63  22.4 vs 68  19.8, P < 0.0001) were worse. RE
(81  23.2 vs 37  43.5, P¼ 0.10) remained similar. [THR vs reference population] THR achieves similar BP (63  28.1
vs 69  26.9, P ¼ 0.19), GH (63  22.4 vs 62  25.0, P ¼ 0.94), SF (62  23.8 vs 65  21.8, P ¼ 0.36), RE (81  23.2 vs
79  24.7, P ¼ 0.53), and MH (79  19.1 vs 72  43.0, P ¼ 0.90) scores. PF (54  27.2 vs 69  31.3, P ¼ 0.01), RP
(45  44.6 vs 60  46.0, P ¼ 0.05) and VT (59  46.4 vs 72  43.0, P ¼ 0.05) were worse.
Function Satisfaction: 96% of patients were satisﬁed in general at the 7 yrs follow-up, and 97% were satisﬁed with their pain
relief and improved physical function. Walking ability>3 km [THR vs reference population] (59% vs 70%, P ¼ 0.15).
Rat25 (2010) To compare QOL scores 3 and 10 yrs after THR for OA with age and sex-
adjusted QOL scores in a general population, and to determine factors
associated with QOL after surgery.
Sex and GP-matched
population
3 yrs and 10 yrs
3, 10 yrs After THR, impaired HRQOL
persists over time despite
substantial improvement in
condition.
Comorbidities, environmental
factors and the presence of
painful locations other than the
THR location are the main
factors associated with post-op
QOL.
Pre-op QOL is predictive of QOL
at 3 yrs but not 10 yrs after
surgery.
Disease speciﬁc measures HHS: [10 yrs vs 3 yrs] total score (47.9  11.3 vs 41.4  13.2, P ¼ 0.002) continues to improve over time.
WOMAC: [10 yrs vs 3 yrs]: Function (52  26 vs 66  21, P < 0.0001) and pain (57  26 vs 70  21, P < 0.0001)
worsens.
OAKHQOL [10 yrs vs 3 yrs]: Physical activities (44  26 vs 57  24, P < 0.0001), MH (61  26 vs 72  22, P < 0.0001),
pain (54  32 vs 66  25, P ¼ 0.003), and social support (65  28 vs 58  28, P ¼ 0.08) improved and social activities
(59  29 vs 64  30, P ¼ 0.22) remained similar.
Generic instruments SF-36: At 3 yrs, PF (37.1  22.2), MH (55.3  19.3), pain (34.0  15.3), and SF (62.7  23.2).
NHP: At 3 yrs, Physical abilities (48.8  20.8), emotional reaction (73.9  27.8), pain (291  25.9), and social isolation
(83.7  25.1).
WHOQOL-BREF: HRQOL scores signiﬁcantly lower than reference population at 3 and 10 yrs (P < 0.05).
Function Walking distance: [10 yrs vs 3 yrs] (1928  2180 m vs 1346  1489 m, P ¼ 0.02).
Hossain56 (2011) To investigate the effect pre-op MH-assessed as psychological distress has on
patient satisfaction after THR.
Post-op vs pre-op
Untreated controls
5 yrs Generic HRQOL improves.
5 yrs patient satisfaction after
THR is very high and although
patients with pre-op mental
distress report less pain relief,
they remain no less satisﬁed
than those without any mental
distress.
Perception of improvement in
QOL similar in both groups of
patients.
Disease speciﬁc measures NR
Generic instruments SF-36: Patients reported a very good improvement in their QOL, with 85.3% responding that they had experienced a
great or more than imagined improvement, and 10.7% responding that they had experienced a moderate
improvement in their QOL.
Patient results in non-distressed were higher than distressed in all subscales (P< 0.01) (non-distressed vs distressed):
PF (21 vs 13), SF (50 vs 26), VT (44 vs 26), RE (59 vs 15), RP (11 vs 5).
Function Satisfaction: very satisﬁed (80.9%), somewhat satisﬁed (16.0%), somewhat dissatisﬁed (2.8%), very dissatisﬁed (0.2%).
Lavernia58 (2011) To determine if there is a gender difference in patient-perceived functional
measures and range of motion in primary THR.
Male vs female
Post-op vs pre-op
Mean
5.6 yrs
(2e16)
Disease-speciﬁc and generic
HRQOL improve in all domains
compared to pre-op.
Both genders had
improvements in all outcome
measures after surgery.
Disease speciﬁc measures HHS: [post-op vs pre-op] Scores more than double for males (84.3  13.9 vs 40.1  14.4) and females (82.7  13.3 vs
36.5  14.8).
MAP: [post-op vs pre-op] Male e (14.4  5.00 vs 10.4  3.03) Female e (14.7  4.51 vs 9.37  3.05)
WOMAC [post-op vs pre-op]: All domains improved. Male e function (9.03  12.9 vs), pain (1.90  3.72 vs), and
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stiffness (0.75  1.40 vs 3.34  2.41). Female e function (8.24  12.5 vs), pain (1.44  3.19 vs), and stiffness
(0.62  1.37 vs3.81  2.46).
Generic instruments SF-36: [post-op vs pre-op] Both
males e PF (59.7  27.1 vs
23.1  20.7), BP (67.0  28.4 vs
38.6  21.5), SF (79.2  26.1 vs
53.7 31.2), PCS (42.4 10.9 vs
28.3  7.21) and females e PF
(53.6  28.3 vs 23.1  20.7), BP
(63.1  27.9 vs 31.3  21.5), SF
(77.1 26.8 vs 42.5 33.4), PCS
(40.8  11.4 vs25.7  7.39) and
improvements in all domains.
Function NR
Mariconda57 (2011) To evaluate patients undergoing THR > 11 yrs ago have severe functional
impairment, and to identify possible outcome predictors of long-term HRQOL
and hip function after THR.
Age-matched population Mean
16  3.6 yrs
Disease-speciﬁc and generic
HRQOL is worse compared to
age-matched populations.
Patients who had undergone
THR have impaired long-term
self-reported physical QOL and
hip functionality, but they still
perform physically better than
untreated patients with
advanced hip OA.
Post-surgical satisfaction is
high.
Disease speciﬁc measures WOMAC: [THR vs reference population] Total score (28.8  20 vs 3.1  7), function (23.6  16 vs 1.8  5), stiffness
(1.2  2 vs 0.4  1), and pain (3.8  4 vs 0.8  2) (P < 0.05 for all domains) was worse.
HHS [THR vs reference population]: total (74.8  17 vs 94  82, P < 0.05).
FCI: 3.6  1.9 pre-op
Generic instruments SF-36: [65e74 yrs THR patients vs reference population]: Scores wereworse in all domains (P< 0.05): PF (44.1 26 vs
71.7  24), RP (50.0  42 vs 65.9  38), BP (48.5  20 vs 67.6  26), GH (41.2  16 vs 55.4  19), VT (49.1  16 vs
59.3  19), SF (57.6  22 vs 75.8  23), RE (65.3  42 vs 73.5  34), MH (54.5  13 vs 64.7  19), PCS (35.3  10 vs
42.7  9), MCS (44.8  9 vs 45.8  9).
Please refer to original article for detailed quantitative results.
Function Satisfaction: 96% of patients were satisﬁed with the outcome of the surgery, and 96.8% said that they would undergo
the same procedure again
Abbreviations: M emen; NR e not recorded; Pe prospective; QOL e quality of life; Re retrospective; Re e recorded; RE e role emotional; RP e role physical; SF-12 emedical outcomes survey short form 12 questions; SF-36 e
medical outcomes survey short form 36 questions; VT e vitality; W e women.
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Table III
Outline of HRQOL scoring systems
System Components
WOMAC35 24 items measuring three subscales. Higher scores indicate worse outcome.
Pain Walking, stairs, bed, sitting, lying, standing
Stiffness After waking and later in the day
Physical function Stairs, rising from sitting, standing, bending, walking, shopping, socks, bathing, toilet, household duties
HHS36 10-items measuring four conceptual domains. Higher scores indicate better outcome.
Pain Severity, effect on activities, pain medication
Function Daily activities and gait assessment
Absence of deformity Hip ﬂexion, adduction, internal rotation, extremity length discrepancy
Range of motion Hip ﬂexion, abduction, external and internal rotation, and adduction
MACTAR39 19 items assessing physical function. Higher effect size indicate better outcome.
OAKHQOL40 43 items assessing ﬁve dimensions. Higher scores indicate better outcome.
Physical activity, mental health, pain, social support, social activities
FCI42 18 items assessing burden of comorbidities on physical function.
Arthritis, osteoporosis, asthma, chronic obstructive pulmonary disease, angina, congestive heart failure, myocardial infarction,
neurological disease, stroke or TIA, peripheral vascular disease, diabetes, upper gastrointestinal disease, depression, anxiety or
panic disorders, visual impairment, hearing impairment, degenerative disc disease, obesity and/or BMI
SF-3644 SF-1246 36 (or 12) items measuring eight conceptual domains or dimensions of health. Higher scores indicate better outcome.
General health (GH) Measurement of perceived overall health, including past and present health
Physical functioning (PF) Indicates level of limitations in lifting, bending, kneeling, or walking moderate distance
Bodily pain (BP) Represents the intensity, frequency, and duration of bodily pain and limitations in normal activities
due to pain
Mental health (MH) Measures the emotional, cognitive, and intellectual status of the patient
Role physical (RP) Measures the degree in performing of usual activities for age and social status
Role emotional (RE) Measures personal feeling of job performance at work or other activities
Vitality (VT) Measures feeling of energy, fatigue, and tiredness
Social functioning (SF) Indicates ability to develop and maintain mature social relationships.
Note: Both SF-36 and SF-12 surveys can provide two summary measures e Physical Component Score (PCS) and Mental
Component Score (MCS)
NHP47 38 yes/no statements on health problems covering six dimensions of subjective health. Higher scores indicate worse outcome.
Physical mobility Only walk indoors, difﬁcult to bend, unable to walk, trouble with stairs, difﬁcult to reach for things,
difﬁcult to dress, hard to stand for long times, needs help walking outside,
Pain Pain at night, unbearable pain, pain on movement, pain on walking, pain on standing, constant pain,
pain with stairs, pain on sitting
Sleep Require sleeping tablets, early morning wakening, awake most of the night, takes a long time to
get to sleep, insomnia
Energy level Tiredness, everything is an effort, easily run out of energy
Emotional reactions Feeling down, anhedonia, feeling on edge, day seems to drag, easily lose temper, feel like losing control,
ruminating at night, feel like life is not worth living, wake up feeling depressed
Social isolation Feeling lonely, difﬁcult to make contact with people, feels close to no one, feel like a burden to people,
difﬁculty interacting with people
SIP48 12 items assessing physical and psychological domains. Higher scores indicate worse outcome.
Physical Ambulation, mobility, body care, movement
Psychosocial Social interaction, communication, alertness behaviour, emotional behaviour, sleep, eating, home
management, reaction, pastimes, employment
WHOQOL-BREF49 Physical health Activities of daily living, medication dependence, energy and fatigue, mobility, pain and discomfort,
sleep and rest, work capacity
Psychological Bodily image and appearance, negative feelings, positive feelings, self-esteem, spirituality, thinking, learning
Social relationships Personal relationships, social support, sexual activity
Environment Financial resources, freedom, safety, security, health and social care, home environment, opportunities
for acquiring new information and skills, participation in opportunities for recreation, pollution, transport
L. Shan et al. / Osteoarthritis and Cartilage 22 (2014) 389e406398corrected by multiplying by (1) to ensure that all positive HRQOL
scales have the same direction of effect. The consistency of results
across studies was assessed by the Tau2 statistic for clinically
relevant heterogeneity51 and I2 statistic for statistical heterogene-
ity52. A P-value <0.05 was considered signiﬁcant for pooled
response means. All statistical analysis was performed on Review
Manager (RevMan) [Windows] version 5.1 (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2011).
Risk of bias
The risk of bias in individual studies was assessed by a quali-
tative review based on study quality and data tabulated in Table I.
Risk of bias across studies was analysed by Tau2 and I2 statistic as
well as Funnel plots to assess for publication bias (Figs. 4 and 5).
Outliers were annotated on the Funnel plots. These analyses of risk
of bias facilitate more accurate interpretation of the qualitative and
quantitative ﬁndings of this review by allowing assessment of
strength of evidence and effects of bias on the ﬁndings.Results
Study selection
After careful systematic selection, 20 studies were selected for
review7,20,25,26,45,53e67 (Fig. 1). Meta-analysis was performed on
pre-operative HRQOL scores compared to post-operative scores at
the time of ﬁnal follow-up for both disease-speciﬁc and generic
HRQOL instruments. Heterogeneous data prevented complete
meta-analysis and precluded analysis of comparisons with refer-
ence populations. Key factors were statistical (no pre-operative
data, data not expressed as mean  standard deviation (SD), etc.)
and methodological (speciﬁc follow-up time point not given for the
respective HRQOL score, use of different HRQOL scoring systems
that could not be amalgamated, etc.) inconsistencies. Hence nine
studies were excluded completely from meta-analysis7,25,53,55e
57,61,65,66. Five studies were excluded from pooled analysis due to
poor study quality (Table I)20,45,59,60,67. Key factors considered were
sample size, response rates (RR) and overall level of evidence.
SEARCH ALGORITHM
31/12/2012
MeSH Keywords
“Total Hip Replacement” AND “Quality of Life”
Limiters
AND Publication date ≥”2000”, AND Language “English” 
326 ARTICLES IDENTIFIED
31 ARTICLES SELECTED
20 ARTICLES7,20,25,26,45,53-67
Being appropriate for this review due to relevancy to this 
topic and scientific accuracy of the reported results
PLUS MANUAL SEARCH OF
EMBASE, MEDLINE, EBSCO DATABASES AND
BIBLIOGRAPHIES OF EACH INCLUDED STUDY
9 ARTICLES7,20,56,58,60,61,64,65,67
295 articles EXCLUDED
82 <3yrs follow-up
16 reviews and expert opinions
4 not in humans
193 not osteoarthritis/THR/primary 
procedure/HRQOL data
Do not meet eligibility criteria
22 articles EXCLUDED
3 <3yrs follow-up
2 follow-up duration not specified
1 not English
3 poor or inadequate results
13not osteoarthritis/THR/primary 
procedure/HRQOL data
Do not meet eligibility criteria
First stage
Second stage
Screening
Screening
40 ARTICLES SELECTED
Fig. 1. Search algorithm.
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sults of six studies (mostly level of evidence II/III)26,54,58,62e64.
Complete standardised response means without pooled analysis
are shown in the Supplementary Figure.
Study characteristics and risk of bias within studies
THR was performed on patients with a primary diagnosis of OA
(mean/median age: 54e91.5 years). The number of patients in each
study was small with less than 500 patients in 15 studies which is a
source of bias20,25,26,45,54e57,59e63,65,66. SF-36 with WOMAC and/or
HHS scores was the most common HRQOL assessment combina-
tion20,25,26,54,55,57e60,62,64. Where a generic HRQOL instrument is
not used there may be inadequate assessment of HRQOL accordingto the WHO’s HRQOL deﬁnition, but this was only in two
studies61,67.
Mean or median follow-up period of included studies ranged
between 3 and 12.8 years. The follow-up consistency was variable.
According to previous guidelines, a RR of >85% (loss to follow-up
<15%) is considered ideal for treatment received analyses32. This
was not achieved in 11 studies20,25,45,55e57,59,60,65e67 with ﬁve
studies having a RR of 27e58%20,56,59,60,67. Patients who do not
participate in HRQOL assessment or are lost to follow-up are more
likely to be more ill and have a worse HRQOL7,25. Thus inclusion of
the above studies for qualitative and meta-analysis is likely to skew
HRQOL results positively. There was a relatively wide SD, range or
CI amongst studies, and reﬂects the inexact subjective nature of
HRQOL.
Fig. 2. Post-operative vs pre-operative disease-speciﬁc HRQOL.
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cles. Seven studies were retrospective45,53,57,58,61,65,67 and only one
randomised controlled trial was present in this review63. This may
reﬂect the ethical dilemma of denying patients surgery when
technical outcomes are excellent. Only eight level I or II studies
were included in this review25,26,54,56,59,63,64,66. Since the strength
of evidence cannot exceed that of included studies, it is limited and
is a major contributor to bias within studies.
Results of individual studies
Disease-speciﬁc quality of life measures
Results of disease-speciﬁc scoring systems were recorded in 15
studies20,25,26,54,55,57e64,66,67 (Table II).
Most of these studies indicate that post-operative WOMAC
and HHS scores were superior up to 16 years compared to
baseline20,25,54,58,59,61e64. The pooled response means of total HHS
[3.59 [2.27, 4.91], P < 0.00001, Fig. 2(A)], and combined WOMAC
and HHS pain [2.33 [1.59, 3.08], P ¼ 0.00001, Fig. 2(B)] and
physical function [2.31 [1.46, 3.16], P < 0.00001, Fig. 2(C)] scores
demonstrated marked beneﬁts for a follow-up of between 3.6
and 7 years. Some studies described improvements on WOMAC
and HHS until 12e18 months with a subsequent plateau effect
where there were no further signiﬁcant gains26,64. Compared to areference population, results vary. Two authors report poorer
scores in all WOMAC domains54,57, and one author reports su-
perior WOMAC pain and stiffness domains with similar physical
function26.
Generic HRQOL instruments
Results of generic HRQOL instruments were recorded in 18
studies7,20,25,26,45,53e60,62e66 (Table II).
SF-36 scores were equal to or better compared to patients’ pre-
operative state in most or all domains for up to 10
years7,20,25,45,54,59,60,62,64. Physical functioning (PF), role physical,
and bodily pain (BP) experienced the greatest improvements. On
quantitative analysis, SF-36 PF [1.16 [0.70, 1.63], P < 0.00001,
Fig. 3(B)], BP [1.23 [0.75, 1.72], P < 0.00001, Fig. 3(C)], role physical
[1.00 [0.40, 1.60], P ¼ 0.001, Fig. 3(E)], role emotional [0.56 [0.02,
1.10], P ¼ 0.04, Fig. 3(F)] and social functioning (SF) [0.42 [0.04,
0.81], P ¼ 0.03, Fig. 3(H)] were improved over a follow-up period of
3.6e7 years. General health (GH) [0.28 [0.80, 0.24], P ¼ 0.29,
Fig. 3(A)], mental health (MH) [0.20 [0.30, 0.70], P ¼ 0.43,
Fig. 3(D)] and vitality [0.36 [0.15, 0.87], P¼ 0.17, Fig. 3(G)] domains
remained similar. SIP scores mirror these beneﬁts63. Some studies
suggest that after a period of 1e3 years, BP, vitality, and PF may
begin to decline, but disease condition and HRQOL appears to
remain above pre-operative levels25,26,53,64.
Fig. 3. Post-operative vs pre-operative generic HRQOL (SF-36).
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comparable or superior HRQOL relative to a reference population
(Table II)45,54,55,58,62,65. All SF-36 domains are shown to be similar or
superior to reference populations by a number of authors at 3, 5, 11
and 13 years54,55,58,62. However, these improvements may be time-
limited and a plateau is reached at 3 years25. Busija et al. report
worse physical function, role physical, BP and role emotional do-
mains, but similar GH, vitality, social function and MH at 5 years45.
NHP scores at 5 years show THR patients have similar energy, pain,
sleep, and emotional reaction, and worse physical mobility
compared to conservatively treated and control populations65.
Functional status and satisfaction
Functional status and satisfaction was assessed in eight
studies25,26,54,56,57,62,66,67.
Between 84% and 97% of patients were satisﬁed with the
outcome of surgery up to 7 years’ follow-up after THR
(Table II)26,54,56,57,66. Up to 95% of patients were satisﬁed with their
ability to practice leisure activities and 96.8% would undergo the
same procedure again57. Nilsdotter et al. reported that 97% were
satisﬁed with the level of pain relief and improved physicalfunction26. At least 80% of patients progressed to an unassisted
limp-free gait by 3e6 weeks62,67, and at 3.6 years, 42% had un-
limited walking distance and only 33% used walking assistance54.
Although walking distance and the number of outdoor daily walks
decreases from 3 to 10 years, the amount of domestic assistance
required and the number of people who use walking sticks de-
creases25. Hossain et al. report that 60.5% of patients were very
satisﬁed with their ability to do house/gardenwork and 53.2% were
very satisﬁed with their ability to do recreational activities56.
Predictors of post-operative QOL
Four studies investigate predictors of mid-term post-operative
HRQOL7,25,54,57. Common predictors of worse outcome in these
studies were female sex, older age, and pain reported at other sites.
Better baseline PF, hypertension (HTN), living alone, and no post-
operative employment may also inﬂuence HRQOL.
The rapidly ageing population and increasing life expectancy
necessitates consideration of HRQOL after THR in the elderly.
Mean or median age of patients was greater than 70 years in six
studies25,26,45,53,54,61. HRQOL was favourable when compared
to before surgery26,45,54,61, but increasing age appears to be a
Fig. 4. Funnel plots of post-operative vs pre-operative disease-speciﬁc HRQOL.
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tients54,57. Discretion is required when operating in nonagenar-
ians, but due to impaired vision and poor balance being possible
confounding inﬂuential factors, HRQOL in this age group is
unclear61.
Long-term post-operative QOL
Long-term post-operative HRQOL is also important. Even
though only ﬁve studies had follow-up data of 10 or more
years25,53,55,57,62, these results may be used to extrapolate our mid-
term ﬁndings to long-term HRQOL. All health domains on NHP and
SF-36 appear to decline progressively from 2 years to 10 years post-
operatively25,53. Butler et al. report all domains on SF-36 except for
BP, GH and role emotion improve markedly at 11 years62. HRQOL is
worse on SF-36 at 10 years25 and both HHS and SF-36 at 16 years57.
Gotze et al. report that at 12 years, SF-36 scores are similar to
population norms in those greater than 70 years of age, but worse
than population norms in those less than 60 years of age in all
domains except GH and social function55. The small number of
studies and conﬂicting data means more studies on long-term
HRQOL are required.
Risk of bias across studies
Statistical (Tau2 range: 0.0e0.0) and clinically relevant hetero-
geneity (I2 range: 0e0%) was minimal amongst studies included for
pooled analysis. However, overall qualitative analysis demonstrates
signiﬁcant heterogeneity between studies. Key factors contributing
to heterogeneity include a wide variation of implants such as sur-
gical approach, bearing surface and ﬁxation method, different pa-
tient demographics such as age, different follow-up times, and use
of different HRQOL instruments.
We aimed to minimise reporting bias by conducting a full and
comprehensive search of the literature using both electronic and
manual search techniques. All identiﬁed articles were retrieved.
Relatively good symmetry was found on funnel plot analysis ofstudies included for pooled responsemeans indicating low levels of
publication bias. Two studies were identiﬁed as outliers which
skewed the results positively in some subgroups26,62.
Discussion
Summary of evidence and interpretation
Recent studies establish a positive impact of THR on HRQOL18,22.
Even though systematic and scoping reviews have previously been
published21,68,69, most of these studies demonstrated a broad range
of beneﬁts on HRQOL up to 2 years after surgery. There are many
factors which can inﬂuence mid-to-long-term HRQOL that are not
reﬂected in these studies. In particular, comorbidities, medication
use, psychological proﬁle, and social support factors impact HRQOL
outcomes and are likely to worsen with time21. Prosthetic failures
and complications also mainly occur after 2 years which is detri-
mental toHRQOL21. Furthermore,weconsidered theuseof a disease-
speciﬁc and/or generic HRQOL instrument as critical to assess the full
deﬁnition of HRQOL and an analysis of each study’s quality was also
undertaken. To our knowledge, this is theﬁrst systematic reviewand
meta-analysis on mid-term HRQOL outcomes after THR.
It is reported that disease-speciﬁc measures may be more ac-
curate for assessing immediate effects of treatment and generic
measures may be more appropriate for revealing the long-term
effects of THR on overall function20. This review demonstrates su-
perior post-operative disease-speciﬁc and generic HRQOL
compared to baseline as illustrated by both qualitative and quan-
titative analysis. The relationship between positive disease-speciﬁc
and generic HRQOL physical domains demonstrates that hip func-
tionality, which is reﬂected by disease-speciﬁc scores such as
WOMAC and HHS, is critical to general function57. Hip-speciﬁc
HRQOL beneﬁts greatly from surgery. Quantitative analysis
showed all health domains on SF-36 were superior or similar to
baseline over follow-up of up to 7 years. PF, BP, and role physical
domains all demonstrated large beneﬁts. These beneﬁts for
Fig. 5. Funnel plots of post-operative vs pre-operative generic HRQOL SF-36.
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objectives of surgery. In addition, role emotional and SF domains’
improvements support signiﬁcant psychosocial beneﬁt from THR
even though this may not be a primary goal of surgery. The lack of
improvement in GH may reﬂect the fact that THR alone is unlikely
to directly improve a patient’s present health status related to theircomorbidities. Some studies also indicated a gradual plateauing or
decline in HRQOL after the ﬁrst few years. This is can be attributed
to ageing or an increasing number of comorbidities and multiple
sites of OA70. However, HRQOL remains above pre-operative levels.
Hence our study indicates there are persistent mid-term HRQOL
beneﬁts after THR.
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ﬁrst 3 years. Subsequently, there were mixed results demonstrating
either a plateau effect of sustained improvements or decline toworse
HRQOL compared to the same reference population. However, we
found studies made comparisons to healthy and younger pop-
ulations, often without correcting for important comorbidities such
as musculoskeletal disease (Table II). A previous study by Keener
et al. raised this issue when comparing results to reference pop-
ulations since unfair comparisons are often made when the refer-
ence population does not accurately represent the THR patient
cohort24. Considering that patients being considered for THR often
carrymultiple comorbidities and reference populations are healthier
in general, and do not have medical conditions affecting physical
function such as OA24, HRQOL should not be expected to exceed such
reference populations. By reaching HRQOL levels of reference pop-
ulations, our ﬁndings indicate a very strong beneﬁt of THR.
HRQOL instruments often do not account for patient satisfaction
which is an important outcome of surgery71,72. We found the vast
majority of patients were satisﬁed with the results of their surgery
as well as their ability to undertake activities of daily living. Effec-
tive pain relief and HRQOL and functional improvements following
surgery means many patients would be willing to undergo surgery
again. These excellent results reﬂect the HRQOL beneﬁts conferred
by THR.
Studies show that lack of information and misperceptions can
lead patients to defer or preclude THR as an option to treat their OA
which may contribute to the inappropriate underutilisation of
THR73,74. HRQOL outcomes data are important to avoid exposing
patients to suboptimal care. They also plays a major role in
providing and disseminating relevant health status information
that can be used as a rationale to improve healthcare resource
utilisation21,75. This is especially important given the burgeoning
demand for THR.
The excellent technical outcomes of surgery are well-
established and the focus is now about improving HRQOL. The ef-
fect of an ageing population and increasing life expectancy with a
relatively stable age at the time of surgery, combined with excellent
long-term prosthetic survival means patients will live with their
implants for a longer time. Prolonged HRQOL beneﬁts are also
particularly relevant for the greater numbers of younger patients
being considered for surgery. Hence maintaining high standards of
HRQOL in the mid-term should be a critical measure of successful
outcome.
Patients expect improvements in physical function after surgery
to be able to lead an active lifestyle19 and realistic expectations also
aid their recovery19,25. Our ﬁndings allow patients to have accurate
expectations on not just physical and functional, but also emotional
and mental welfare after surgery. This review demonstrates that
there is increasing evidence showing worthwhile gains in regards
to mid-term HRQOL after THR. Surgeons, patients, and their fam-
ilies can be more conﬁdent about the mid-term HRQOL beneﬁts of
undergoing THR when it is required.
Review limitations
The primary limitation of this review is that only a limitedmeta-
analysis could be performed. We have attributed this to the clinical
and methodological heterogeneity between studies. As a result, the
large proportion of studies unable to be included for meta-analysis
means the quantitative results may be skewed. Nevertheless, the
magnitude and signiﬁcance of the quantitative results, as well as
the very low Tau2 and I2 values, supports the results of qualitative
analysis showing that THR is effective at improving HRQOL.
The ﬁndings of this review should be interpreted with caution.
There were six studies which had very low RR20,56,59,60,62,67, ofwhich four were evidence level III20,60,62,67. Whilst these factors
contribute to bias in this review, they reﬂect the deﬁciencies in
currently available evidence. This review provides a useful syn-
thesised modern reference when considering patients for surgery.
Implications for future research
THR is a high calibre and frequently performed operation. Un-
derstanding the mid-term implications when considering a patient
for surgery is necessary. This review identiﬁes a few key areas
which need to be addressed in future studies.
The most important method of accurately determining HRQOL
is by using previously validated HRQOL instruments. The SF-36
instrument is preferred due to the majority of studies reporting
this systemwhich would facilitate quantitative analysis. Telephone
interviews are preferable and repeated attempts at contact to
minimise loss to follow-up are advised. The study should have a
prospective design with pre-determined follow-up time points at
baseline and at least yearly thereafter. An important area of future
research would be focussed on long-term HRQOL. Patients should
have their pre-operative baseline HRQOL scores compared to post-
operative scores at each time point. All results should be recorded
as mean  SD. Multicentre involvement is ideal to increase patient
numbers and minimise bias from single centre studies.
Conclusion
The most important ﬁndings of this systematic review and
meta-analysis are that mid-term HRQOL following THR (1) is su-
perior to pre-operative levels in a broad range of HRQOL domains,
(2) can reach the levels of reference populations, and (3) results in
good patient satisfaction and speciﬁc functional gains. A thorough
evaluation of patients for THR is still encouraged. In the absence of
large randomised controlled trials, these ﬁndings must be consid-
ered in conjunction with clinical decision making tailored to each
patient.
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